In patients suffering from the genetic syndromes of severe insulin resistance it appears that diabetes develops when the adaptive hypersecretion of insulin fails and often these forms of diabetes will be insensitive to insulin treatment. The objective of the present study was to examine the metabolic and hormonal responses to an unchanged insulin therapy with the addition of a subcutaneous administration of recombinant human IGF-I (rhIGF-I) during (a) a short-term (2 weeks) period with rhIGF-I given twice a day in a high dose (80 \g=m\g/kgbody weight) in four patients with extreme insulin-resistant diabetes mellitus and (b) during a long-term (10 weeks) period with rhIGF-I given once a day in a low dose (40 \g=m\g/kgbody weight) in three of the four patients. Two siblings had known mutations in the tyrosine kinase domain of the insulin receptor and a deletion of exon 17 in part of their insulin receptor mRNA, whereas the remaining two patients were suspected to have defects at receptor and/or post-receptor sites. In the short-term study period, plasma glucose levels decreased more than 35% in response to rhIGF-I in all but one patient which was paralleled by reduced levels of serum insulin (25\p=n-\50%), proinsulin (40\p=n-\50%) and C-peptide (10\p=n-\65%) and an improvement in glycaemic control as evaluated by decreased glycosylated haemoglobin and serum fructosamine. During the long-term study period blood glucose-lowering effects of rhIGF-I were seen after 2 weeks of treatment and fasting plasma glucose and serum insulin and C-peptide levels were decreased by 40\p=n-\55% after 6 weeks in the two siblings with known insulin receptor mutations. After 10 weeks of treatment fasting plasma glucose levels were still decreased whereas fasting serum insulin and C-peptide levels were increased almost to pretreatment values. In conclusion: 2 weeks of high-dose rhIGF-I therapy in insulin-treated patients with severe insulin resistance has a marked lowering effect on fasting plasma glucose and serum insulin levels whereas the metabolic and glycaemic effects of 10 weeks of treatment with l ow\x=req-\ dose rhIGF-I may be modest and transient.
Introduction
The genetic syndromes of extreme insulin resistance are commonly associated with acanthosis nigricans, a hyperkeratotic hyperpigmented skin lesion, and ovarian masculinization (1) . A series of different mutations in the insulin receptor gene is associated with some of the syndromes of severe insulin resistance, whereas postreceptor molecular defects are likely to be dominant in other cases of severe insulin resistance (1) . The insulin resistance in these syndromes is often compensated by a marked increase in endogenous insulin secretion. However, when this adaptation is insufficient frank diabetes mellitus that does not respond adequately to insulin therapy occurs.
Insulin-like growth factor-I (IGF-I) is a 70 amino acid peptide that regulates growth and development as well as metabolism. The actions of IGF-I result from the integration of its effects on cellular proliferation, overall anabolism, and the synthesis of specific macromolecules that support differentiated function (see (2) for review). IGF-I acts through IGF-I or insulin receptors or hybrids of these receptors (3) . The IGF-I receptors are present at high concentrations in muscle (2) and IGF-I may thus stimulate glucose transport and glycogen synthesis, primarily via its own receptor (4, 5) .
Administration of recombinant human IGF-I (rhIGF-I) to normal subjects leads to a dose-dependent decrease in blood glucose levels and a marked suppression of endogenous serum levels of insulin and C-peptide (6, 7) .
From studies of patients with extreme insulin resistance due to the type A insulin resistance syndrome, admin¬ istration of intravenous rhIGF-I resulted in an immedi¬ ate fall in blood glucose and the markedly elevated circulating levels of insulin and C-peptide fell in a par¬ allel manner (8) . Subcutaneous During the short-term study period, total serum IGF-I, plasma IGFBP-1, plasma IGFBP-3 and anti-IGF-I were all analyzed using RIAs (performed by Pharmacia AB). For IGF-I (normal range: 119-262 ng/ml) the detection limit for undiluted samples was 20 ng/ml and the intraand interassay coefficients of variation (at a concen¬ tration of 200 ng IGF-I/ml) were 0-03 and 0-10 respectively. The cross-reactivity for IGF-II was approxi¬ mately 1%, whereas for insulin, proinsulin and smaller IGF-I fragments the cross-reactivity was negligible. For IGFBP-1 (normal range: 6-74-12-46ng/ml) the mea¬ suring range was 1-8-178 ng/ml and the intra-and interassay coefficients of variation were 0-03 and 0-13 respectively. Cross-reactivity for plasma IGFBP-3 was below 0-003%. For plasma IGFBP-3 (normal range: 3-21-5-15 mg/ml) the measuring range was 0-075-128 µg/ml and the intra-and interassay coefficients of variation were 0-05 and 0-07 respectively. Crossreactivity for IGFBP-1, IGFBP-2 and IGFBP-4 was below 0-3%. Samples for anti-IGF-I yielding a titre of >l-0 were considered positive for anti IGF-I, a titre below <1 was not significantly increased. Measuring range for positive control rabbit serum was &3/ig/l. 
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The intra-and interassay coefficients of variation for positive test were 0 5 and 0-15 respectively. During the long-term study period, total serum IGF-I and plasma IGFBP-1 were analyzed as described previously (19, 20 (Table 3) .
HbAlc, which had been elevated in all patients for more than 3 months, decreased in all study participants after 14 days of combined rhIGF-I and insulin treat¬ ment and remained decreased during the study period (Table 3 ). The reduction of hyperglycaemia was further confirmed by measuring serum fructosamine.
In all patients, highly variable fluctuations were seen in fasting serum IGF-I concentrations from day 0 to week 10 (Table 3) . No changes were seen in fasting serum IGFBP 3 levels in patients and D, whereas a small increase was seen in patient C (24%) after 10 weeks of IGF-I treatment (Table 3) .
IVGTT during long-term rhIGF-I treatment IVGTT tests were performed in all three patients at the initiation of the study and after 6 and 10 weeks of treatment. A clear decrease in plasma glucose area under the curves (AUC) was seen in patients (39%) and C (41%) and to a lesser extent in patient D (21%) after 6 weeks of rhIGF-I treatment despite lower fasting serum insulin levels (Table 3 ). After 10 weeks of treatment a small increase was seen when com¬ pared with results after 6 weeks. For serum insulin and C-peptide AUC, smaller decreases were seen after 6 weeks of treatment (5-26 and 12-34% respectively).
However, after 10 weeks of treatment, AUC values for serum insulin and C-peptide were comparable with pretreatment levels (Table 3) .
IGF-I effects on the cardiovascular system Short-term rhIGF-I treatment (days 1-15; 80/ig/kg bw twice a day) had effects on blood pressure and/or heart rate in some of the patients when compared with baseline levels (day 0) (data not shown). The effects were most marked in patient with an increase in heart rate, expressed as a percentage of baseline levels, of 187% and on systolic and diastolic blood pressure of 132% and 118% respectively. An increase in heart rate was also seen in patient A (129%) and patient C (109%), whereas heart rate was unaffected by rhIGF-I treatment in patient D (94%). Systolic and diastolic blood pressure was slightly increased in patient A (109% and 112% respectively) and patient C (115% and 119%) whereas a small decrease was seen in patient D (79% and 81%). Only patient D complained of intermittent symptoms of increased heart rate.
During the long-term study period with rhIGF-I (40/xg/kg bw once a day) blood pressure and heart rate, measured every second day by the patients, remained unchanged during the whole period. (3, 24) . Fasting serum insulin and IGFBP-1 levels are inversely corre¬ lated in children and young adults (24) . In the present study, all patients were characterized by having high fasting serum insulin levels at entry and at the end of the study period and fasting plasma IGFBP-1 levels were also decreased in all patients except in patient A. In patient A, where only small changes were seen in serum insulin and serum C-peptide and plasma glucose levels during the study, the plasma IGFBP-1 level was markedly increased both before and at the end of the study period. The (24) or to cause no change in plasma IGFBP-3 levels (26) . Plasma IGFBP-3 levels are increased during puberty and acromegaly and decreased in growth hormone deficiency and diabetes (3) . In the present study, all but one (A) patient were characterized by having very high fasting levels of plasma IGFBP-3 at entry to the study and in all patients an increase was seen in fasting plasma IGFBP-3 after 14 days of rhIGF-I treatment. The abnormal low levels of plasma in patient A at entry to the study together with low levels of serum IGF-I may be due to dysregulated diabetes and/or to a defect in growth hormone-induced stimulation of IGF-I/IGFBP-3 production. Furthermore, low levels of plasma IGFBP-3 increase the clearance of IGF-I leading to reduced circulating IGF-I levels. Patient A had no phenotypic sign of growth retardation. Whether an increased plasma IGFBP-3 protease activity is present in the serum of the patient can only be speculated upon.
IGF-I has noticeable effects on the cardiovascular system, increasing both heart rate and stroke volume producing an increased cardiac output (25, 27) , possibly through IGF-I receptors expressed in cardio¬ vascular tissue (28) . Whether a stimulation of the sympathetic activity takes place due to rhIGF-I infusion during hyperglycaemia is not known. No stimulation has been seen during euglycaemia in man (27) . In the present short-term study, rhIGF-I treatment had effects on blood pressure and/or heart rate in some of the patients when compared with baseline levels (day 0).
The effects were most marked in patient with both an increased heart rate (187% above basal) and increased systolic and diastolic blood pressure (132% and 118% above basal respectively). In the other participants the changes were only minor. During the long-term study, with a much smaller rhIGF-I dose, no effects on the cardiovascular system were observed. These observa¬ tions clearly indicate that the adverse effects of IGF-I treatment are in part dose-dependent.
